Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions. The Nexus platform is driven by a new proprietary digital algorithm that results in more power, efficiency and control. Nexus uniquely incorporates RF capabilities, allowing for use in general surgery procedures. The device also incorporates Smart Technology that allows for easier setup and use.
Physicians will be able to utilize Nexus’ increased power to improve tissue resection rates, in concert with its proprietary digital algorithm to perform more efficient bone removal procedures. In addition, Nexus’ ease of use will enable physicians to fully leverage Nexus’ impressive capabilities via its digital touchscreen display and smart system setup.
Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, commented, “We are very pleased to have achieved this critical approval, marking a significant milestone for Misonix and the culmination of years of hard work.” Nexus is a powerful, highly integrated and easy-to-use system that will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology allowing for increased efficiency and efficacy, and thus improved outcomes. It is truly a transformational product.
“The overwhelmingly positive feedback we have received from the surgeon community since first unveiling Nexus reinforces our confidence in its potential to serve as a significant growth engine for Misonix. Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets. Nexus provides us with a unique opportunity to leverage our robust consignment business model, further drive the sale of consumables competitively, and extend our ability to cross-sell into multiple physician specialties. The commercialization of Nexus will expand the utilization of ultrasonic surgical applications as we continue to strategically invest in our products to become the standard of care in operating rooms and hospital outpatient departments.”
The ADEXUSDx® Analyzer is a portable handheld analyzer that performs blood analysis at the point-of-care for use with the ADEXUSDx® test cassettes, used by healthcare professionals trained and certified to use the ADEXUSDx® System.
Now common in both the medical and motion picture industries, Omnica helped pioneer radio opaque and retro-reflector markers used in medical telemetry and motion capture applications. DFMA and manufacturing fixtures were also developed for prototyping quantities during development.
The HALO® Breast Pap Test is a patented fully automated noninvasive breast disease-screening device for use in physician offices. It is FDA-cleared for the collection of nipple aspirate fluid (NAF) for cytological evaluation. Like the Pap test for cervical cancer, HALO looks for cellular changes years before breast cancer is detectable by mammographic imaging. To learn more about the test and locate a physician who offers it, visit www.neomatrix.com or call (877)-HALOPAP.
In collaboration with AMI Purdue University
One of the most visible projects that Omnica has developed was the family of Becton Dickinson locking sharps collectors that are found in healthcare facilities everywhere. Engineering the tipping point for a .5cc syringe and casting accurate, functional prototypes from silicone soft tooling were two of many challenges confronted and overcome.
Day after day, analytical testing laboratories face considerable challenges due to backlogs of time-critical samples, rising per-sample costs, availability of skilled laboratory technicians, and chromatography maintenance and downtime. The Thermo Scientific™ VeriSpray™ PaperSpray ion source uniquely addresses these concerns. Combine the VeriSpray ion source with next-generation Thermo Scientific™ mass spectrometers to reduce time to results and cost per test with automated, high-throughput, direct mass spectrometry (MS)-based sample analysis. The VeriSpray ion source allows use of “dilute and shoot” methods to minimize solvent consumption and time-consuming sample preparation steps like derivatization, while avoiding needs for expert operators and instrument downtime. For laboratories currently performing LC or GC methods, or for those that want to add the robust sensitivity and selectivity of MS-based tests, the VeriSpray ion source provides an ideal alternative to the complexity of chromatography-based solutions.